| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
CLO &Secretary | Chief Legal Officer & | Chief Legal Officer & +1 more
3 companies
Reardon Andrew serves as a CLO &Secretary at LGND and has filed Form 4s across 3 companies. Across recent SEC filings that breaks down to 0 buys and 67 sells. Those positions are worth an estimated $21.0M at current prices.
Historically, Reardon Andrew's trades have earned a below-average insider score of 26/100 across 7 rated trades. Over a 12-month horizon, 0.0% of those trades were profitable, with an average 12-month return of -63.6%.
The biggest single holding is LGNYZ (~$10.9M) as CLO &Secretary. The recent filings there lean toward selling, a net 25,000 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 15, 2025 | LGND Ligand Pharmaceuticals Inc | CLO &Secretary | Sell | 1,000 | $104.00 | $104,000.00 | -2.9% | +50.8% | +106.1% | |
| Sep 23, 2024 | LGND Ligand Pharmaceuticals Inc | CLO &Secretary | Sale+OE | 2,000 | $99.60 | $199,201.00 | -8.2% | +14.2% | +71.2% | |
| Aug 28, 2024 | LGND Ligand Pharmaceuticals Inc | CLO &Secretary | Sale+OE | 1,500 | $106.39 | $159,590.55 | -6.2% | +16.7% | +50.1% | |
| May 9, 2024 | LGND Ligand Pharmaceuticals Inc | Chief Legal Officer & | Sale+OE | 10,000 | $83.04 | $830,449.00 | -31.1% | +8.4% | +21.3% | |
| Mar 24, 2023 | LGND Ligand Pharmaceuticals Inc | See Remarks | Sell | 300 | $69.92 | $20,977.29 | -1.8% | +9.1% | +2.3% |